Quest Diagnostics Inc
DGX- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001022079
In the last 90 days, Quest Diagnostics Inc insiders filed 0 open-market purchases and 4 sales; 1,115 institutions reported holding it in 13F filings for Q2 2026, worth $22.2B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $28.4B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $13.7M in total
- 4
- 13F holdersQ2 2026, +51 vs. previous quarter
- 1,115
- 13F valueReported value at the end of Q2 2026
- $22.2B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $11.0B
- +11.8% year over year
- Net income, FY2025
- $992.0M
- +13.9% year over year
- Free cash flow, FY2025
- $1.36B
- +49.5% year over year
- Revenue, Q3 FY2026
- $3.10B
- +10.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.73M
- Shares sold short
- Change
- +160.2K
- +4.5% vs. previous
- Days to cover
- 3.64
- At average daily volume
Superinvestors holding DGX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding DGX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Quest Diagnostics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)7:05 PM ET | Nov 3 | 2 days | Doherty Catherine T.Executive Vice President | SSale | −22.1K | $248.02 | −$5.48M | −23.5%71.9K after | 7 lots10b5-1 |
| Oct 28, 2026 (view filing)6:05 PM ET | Oct 26 | 2 days | Pfeiffer Gary MDirector | SSale | −1.20K | $243.00 | −$292.3K | −3.9%29.8K after | 10b5-1 |
| Sep 3, 2026 (view filing)5:05 PM ET | Sep 1 | 2 days | Davis J. E.CEO and President | SSale | −10.0K | $242.72 | −$2.43M | −7.6%122.4K after | 10b5-1 |
| Aug 31, 2026 (view filing)4:37 PM ET | Aug 28 | 3 days | Prevoznik Michael ESVP & General Counsel | SSale | −22.7K | $243.11 | −$5.51M | −37.6%37.6K after | 3 lots10b5-1 |
| Jul 29, 2026 (view filing)5:04 PM ET | Jul 28 | 1 day | Delaney Mark ESVP & Chief Commercial Officer | SSale | −1.60K | $235.18 | −$376.3K | −13.4%10.3K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Kuppusamy KarthikSVP, Clinical Solutions | SSale | −8.15K | $200.00 | −$1.63M | −37.6%13.5K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Davis J. E.CEO and President | SSale | −10.0K | $194.14 | −$1.94M | −7.0%132.4K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Doherty Catherine T.EVP, Regional Businesses | SSale | −5.56K | $206.21 | −$1.15M | −7.6%67.1K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −3.88K | $206.21 | −$799.7K | −9.4%37.6K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Plewman PatrickSVP for Diagnostic Services | SSale | −2.85K | $206.21 | −$588.7K | −15.8%15.2K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 1,115 holdersThe largest institutional positions in Quest Diagnostics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,275,411 | $1.97B | 0.03% | +103,119+1.1% | Added |
| Vanguard Capital Management LLC | 7,233,394 | $1.53B | 0.03% | +87,722+1.2% | Added |
| Vanguard Portfolio Management LLC | 6,131,045 | $1.30B | 0.06% | +49,645+0.8% | Added |
| State Street Corp | 5,516,643 | $1.17B | 0.03% | +135,822+2.5% | Added |
| Price T Rowe Associates Inc | 5,444,986 | $1.15B | 0.12% | −853,001−13.5% | Reduced |
| Boston Partners | 4,744,473 | $1.00B | 0.89% | +732,241+18.3% | Added |
| JPMorgan Chase & Co | 3,520,438 | $748.6M | 0.04% | −326,018−8.5% | Reduced |
| Geode Capital Management, LLC | 3,137,873 | $662.6M | 0.04% | +51,565+1.7% | Added |
| Morgan Stanley | 2,460,497 | $521.5M | 0.03% | −19,223−0.8% | Reduced |
| EdgePoint Investment Group Inc. | 2,247,568 | $476.4M | 3.60% | +3,699+0.2% | Added |
Holders of 5% or more of DGX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Quest Diagnostics Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.40%9.31M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 7.53%8.27M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.54%6.10M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in DGX11 members of Congress reported 28 trades in Quest Diagnostics Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 13, 2026 |  Carol D. Miller House · WV | Sell | $15K-$50K |
| Aug 5, 2026 |  Julie Johnson House · TX | Sell | $1K-$15K |
| Aug 5, 2026 | Julie Johnson House · TX | Buy | $1K-$15K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $1K-$15K |
| Jul 21, 2026 | Alan Armstrong Senate · OK | Buy | $1K-$15K |
House · WV · Aug 13, 2026
Sell$15K-$50K
House · TX · Aug 5, 2026
Sell$1K-$15K
House · TX · Aug 5, 2026
Buy$1K-$15K
Senate · OK · Jul 21, 2026
Buy$1K-$15K
Senate · OK · Jul 21, 2026
Buy$1K-$15K